Treating ARCSA: Transfusions, Chelation, and Transplant

Managing Autosomal Recessive Congenital Sideroblastic Anemia (ARCSA) is a journey that often begins with a trial of a simple vitamin and may lead toward a complex, potentially curative transplant. Because ARCSA—particularly the form caused by the SLC25A38 gene—frequently appears in infancy with severe anemia, the goal of treatment is to support your child’s growth while protecting their organs from the long-term effects of iron buildup ^[1][2].

The Supervised Vitamin B6 (Pyridoxine) Trial

One of the first steps your doctor may suggest is a supervised trial of high-dose pyridoxine (Vitamin B6). This can be confusing for families, as the disease is often historically labeled “pyridoxine-responsive.” It is important to have realistic expectations for this trial.

In the X-linked form of sideroblastic anemia, Vitamin B6 often works well because it helps a specific enzyme (ALAS2) function better ^[1]. However, in ARCSA, the “factory error” is usually in a different part of the heme-making process that B6 cannot easily fix ^[3].

• What the evidence says: In a very small case series of patients with the SLC25A38 mutation, only about 33% (2 out of 6) showed any response to Vitamin B6 ^[3]. This is low-certainty evidence, but illustrates that response is rare.
• The outcome: Even when the vitamin helps, the response is typically “partial” (meaning the anemia doesn’t go away completely) and “transient” (meaning it stops working over time) ^[3].

While a supervised trial is standard to see if your child is among the few who benefit, it is rarely a long-term solution for ARCSA ^[3][1]. Warning: You must never start high-dose Vitamin B6 on your own, as unsupervised high doses can cause severe peripheral sensory neuropathy (nerve damage).

Managing Severe Anemia: Red Blood Cell Transfusions

If Vitamin B6 does not work or stops working, the primary way to manage the disease is through regular red blood cell transfusions ^[4]. These transfusions provide the healthy red blood cells your child’s body cannot produce, ensuring their brain, heart, and muscles get the oxygen they need to grow.

Most children with severe SLC25A38 mutations become “transfusion-dependent” early in life ^[1][2]. The frequency of these transfusions is tailored to your child’s energy levels, growth, and hemoglobin trends, rather than a single “magic number” ^[4]. It is vital to discuss the use of leukoreduced or phenotype-matched blood units to prevent alloimmunization (forming antibodies against the donor blood), as well as how to recognize transfusion reactions.

The Iron Challenge: Monitoring and Chelation

While transfusions are lifesaving, they carry a side effect: iron overload. Every bag of blood contains iron that the body has no natural way to remove. In ARCSA, the situation is even more complex because the body may start absorbing and “trapping” excess iron even before the first transfusion begins ^[3].

To protect the heart and liver from iron damage, your team will use two main tools:

1. Surveillance: This includes regular blood tests for ferritin (an indirect marker of storage and inflammation) and periodic MRI (T2)* scans ^[5]. An MRI is the most accurate way to “see” how much iron is actually deposited inside the organs ^[6].
2. Chelation Therapy: When documented iron burden warrants it, doctors prescribe chelators—medications like deferasirox that bind to iron and help the body flush it out ^[3][7]. The choice depends on age, transfusion burden, and organ iron. Because these medications can affect the kidneys, liver, hearing, or vision, your child will need regular blood and urine tests while taking them ^[8].

The Curative Path: Stem Cell Transplant

Currently, the only established, potentially curative option to stop the need for transfusions is an allogeneic hematopoietic stem cell transplant (HSCT) ^[1]. This procedure replaces your child’s bone marrow “factory” with healthy cells from a donor.

• Success Rates: In a small cohort of children with the SLC25A38 mutation who underwent transplant, the majority became transfusion-free ^[3][9].
• The Importance of Timing: Research strongly suggests that HSCT is most successful when performed early, before significant iron buildup has occurred ^[3]. In one case, a patient with very high iron levels experienced severe complications after transplant ^[3].

However, HSCT is a major procedure carrying severe, life-threatening risks, including conditioning chemotherapy toxicity, severe infections, graft failure, Graft-versus-Host Disease (GVHD), infertility, and transplant-related mortality. Because the risks of transplant are lower when a child is younger and has less organ damage from iron, many experts recommend starting the conversation about a transplant early ^[3][10]. Discussing transplant or doing HLA typing does not commit a family to proceeding. Furthermore, HSCT stops the anemia but does not instantly remove stored iron, so ferritin monitoring may still be required post-transplant.

Your child’s treatment plan will evolve as they grow. Whether through supportive care or a curative transplant, the goal remains the same: a future where your child is supported through careful, shared decision-making.